For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/acute-
heart-failure-ahf-therapeutics-market-1910
Acute Heart Failure (AHF) Therapeutics Market – Competitive Landscape
Some of the key players in this market are Novartis AG, Cardiorentis AG, Bristol-Myers Squibb
Company, Amgen Inc., Bayer AG, Cytokinetics, Inc., Merck & Company, Inc., Ono Pharmaceutical
Co., Ltd., and Pfizer Inc., among others. Key players in the marker are engaged in development of
new drugs for acute heart failure (AHF). These players are incorporating collaboration strategies to
remain competitive in the market.
For instance, in October 2015, Cardiorentis AG announced plans to collaborate with Roche to
establish therapeutic efficacy and safety of Ularitide: Cardiorentis’ investigational drug for acute
heart failure (AHF). Under the terms of collaboration, Cardiorentis will incorporate Roche's
advanced in vitro diagnostic tests into its TRUE-AHF Phase III study to characterize the
pharmacological properties of Ularitide, evaluate its benefit-risk profile, and the appropriate clinical
application in patients.
Acute Heart Failure (AHF) Therapeutics Market Taxonomy
By Disorder Type
•Right-sided Heart Failure
•Left-sided Heart Failure
•Systolic Failure
•Diastolic Failure
•Congestive Heart Failure
By Drug Category
•Angiotensin-Converting Enzyme (ACE) Inhibitors
•Captopril (Capoten)
•Enalapril (Vasotec)
•Fosinopril (Monopril)
•Lisinopril (Prinivil, Zestril)
•Perindopril (Aceon)
•Quinapril (Accupril)
•Ramipril (Altace)
•Others
•Angiotensin II Receptor Blockers
•Candesartan (Atacand)
•Losartan (Cozaar)
•Valsartan (Diovan)
•Angiotensin-Receptor Neprilysin Inhibitors (ARNIs)
•Sacubitril/valsartan